Merck & Company (MRK) 59.28 $MRK
J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
Global Acaricides Market Outlook 2019 - Key Vendors are BASF SE, Arysta LifeScience, Bayer AG, DuPont & FMC Corporation
M2 - Tue Sep 30, 9:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mdhbk/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. The global acaricides market is estimated to be valued at $275.1 million by 2019, at a projected CAGR of 5.2% from 2014 Acaricides are chemicals that are manufactured and used for controlling the spread of arthropod pests. These pests, if allowed to spread, cause huge losses to agricultural crops and also infect various animals in the animal husbandry industry. There are numbers of acaricides available, which have different concentrations of various chemicals like chlorine, phosphorus, zinc, and tin. Acaricides have toxic effects too, due to which natural products like neem, clove, and spoiled corns, are also being used for the production of acaricides. These natural acaricides tend to be less toxic. The Asia-Pacific region is estimated to be the largest consumer of acaricides in the world, followed by Europe. China is estimated as the largest market in the Asia-Pacific, having captured around 44% of the total market in the region, in 2013. This market is growing steadily due to an increase in the usage of crop protection chemicals to control the spread of ticks and mite-borne diseases. The demand-driving factors of this market are developments in the crop protection industry and the rise in demand for meat and dairy products. The restraining factors are the regulatory restrictions in some countries and the rising cost of acaricides. Key participants in the acaricides market are BASF SE (Germany), Arysta LifeScience (Japan), Bayer AG (Germany), DuPont (U.S.), and FMC Corporation (U.S.). The acaricides market is witnessing rapid development in the areas of new product launches, with a focus on increasing the availability of various acaricides in the market and also on increasing their global market share. Scope Of The Report By type - Organochlorine - Organophosphorus - Natural - Others By application - Agriculture - Animal Husbandry - Industrial - Others By mode of application - Spray - Dipping vat - Hand dressing - Others Companies Mentioned - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/9m...des_market
Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
Glaucoma Treatment Market 2014-2019 Global Trends & Opportunities Reviewed in New Research Report
PR Newswire - Tue Sep 30, 7:30AM CDT
MarketReportsOnline.com adds Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) research report that provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Complete report is available at http://www.marketreportsonline.com/357921.html .
Inovio Pharmaceuticals Appoints Vice President of Commercial Development
PR Newswire - Tue Sep 30, 6:00AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into phase III, Ms. Laux will direct commercial development for the company's immunotherapies to treat HPV and the pre-cancers and cancers caused by this infection.
Global and Chinese Chemical Reagent Industry Report 2014-2017
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjcjmv/global_and) has announced the addition of the "Global and Chinese Chemical Reagent Industry Report, 2014-2017" report to their offering. Chemical reagent, purified from industrial chemicals, serves chiefly scientific experiment and detection analysis, and finds massive application in electronic information, medicine, food, aerospace and military industry manufacturing. In 2013, global chemical reagent market was worth about USD 13.6 billion, with market demand concentrated in United States, Europe and Japan. There are a large variety of chemical reagents, totaling above 250,000 around the world. American Sigma-Aldrich is the company that produces the most varieties of chemical reagents, up to approximate 230,000. Global chemical reagent industry characterizes a fairly high concentration, and American Sigma-Aldrich and German Merck Group, as industry leaders, took up a combined 30% or so market share globally in 2013. China chemical reagent industry has developed quickly, achieving a CAGR of 15.9% as concerns market size during 2007-2013, and making up 19.2% of global market size. Chemical reagent can be divided into general reagent and high-purity reagent, with the latter accounting for about 26% of total market size in China in 2013. High-purity chemical reagent is mainly used in semiconductor industry, and is the product that enjoys the fastest growth rate and has the highest technical content and added value. With the rapid development of China's electronic information, biotechnology, national defense, military industry and other industries, the demand for high purity reagent will keep a roughly 15% growth rate over the next couple years. In 2013, there were more than 400 chemical reagent producers with production licenses in China, most of which focused on low-end products, resulting in fierce competition in the low-end market; by contrast, the high-end market is dominated by transnational companies, such as German Merck Group and American Sigma-Aldrich, which held a combined 16.9% market share in China in 2013. In recent years, concentration of China chemical reagent industry has been improving gradually, mainly reflected by rapid development of large chemical reagent companies. Moreover, China-made chemical reagents are advancing from the low-end to the middle and high-end, with some imported products having been substituted with domestic ones. Typical domestic companies include Xilong Chemical Co., Ltd. and Sinopharm Chemical Reagent Co., Ltd., together occupying 13.2% of the Chinese market in 2013. Key Topics Covered: 1. Overview of Chemical Reagent 2. Chemical Reagent Market 3. Chinese Chemical Reagent Market 4. Foreign Companies 5. Chinese Companies 6. Summary and Forecast Companies Mentioned - Anhui Fulltime Specialized Solvent & Reagent - Danaher - Guangdong Guanghua Sci-Tech - Jianghua Microelectronics Materials - Jiangyin Chemical Reagent Factory - Johnson Matthey - Merck Group - Sigma-Aldrich - Sinopharm Group - Suzhou Crystal Clear Chemical - Suzhou JIMCEL Electronic New Material - TCI - Thermo Fisher - Wako - Xilong Chemical For more information visit http://www.researchandmarkets.com/research/sjcjmv/global_and
Hospital Infection Therapeutics (Antibacterial, Antiviral and Antifungal Drugs) Market - Global Pipeline Analysis 2014-2020
M2 - Tue Sep 30, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4q7d8p/hospital) has announced the addition of the "Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future. North America dominates the global hospital infection therapeutics market followed by the European market in 2013. Key factors contributing to the growth of the region are high prevalence of various hospital infections, rising number of multi-drug resistant microbial pathogens, increasing demand for advanced therapeutics, and high ratio of hospitals per thousand of the population. This region also comprises huge geriatric population that are more prone towards different hospital infections due to their lowered immunity levels, hence require use of various antimicrobial therapeutics, which in turn will contribute towards the growth of this market. Asia-Pacific represents the fastest growing geographic region in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. Key factor responsible for the rapid growth of this market is increasing prevalence of hospital-acquired infections in the region. Increasing healthcare awareness and infrastructure along with increasing purchasing power of the people will add to the growth of this market in the region. The global hospital infection therapeutics market is segmented as follows: Hospital Infection Therapeutics Market, by Drug Type - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs Hospital Infection Therapeutics Market, by Major Infections - Hospital-Acquired Pneumonia - Surgical Site Infections - Urinary Tract Infections - Gastrointestinal Disorders - Bloodstream Infections - Other Hospital Infections Companies Mentioned - Actavis plc - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline plc - Johnson & Johnson Services, Inc. - Merck & Co., Inc. - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/4q7d8p/hospital
Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 5:50PM CDT
A response from the FDA on Bristol-Myers' (BMY) Opdivo should be out by Mar 30.
Endocyte's TARGET Interim Data Positive for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:25PM CDT
Endocyte, Inc. (ECYT) announced an encouraging interim update on overall survival (OS) of patients in the phase IIb TARGET study on vintafolide for NSCLC.
Research and Markets: Global Therapeutic Vaccines Market Outlook 2019 Featuring GSK, Merck, Novartis, Pfizer, Sanofi Avnetis & Serum Institute
Business Wire - Mon Sep 29, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vl7kz/global) has announced the addition of the "Global Therapeutic Vaccines Market- Trends And Forecasts (2014-2019)" report to their offering.
Why Endocyte, Inc. Stock Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 29, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
Global Therapeutic Vaccines Market Outlook 2019 Featuring GSK, Merck, Novartis, Pfizer, Sanofi Avnetis & Serum Institute
M2 - Mon Sep 29, 11:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t44dgp/global) has announced the addition of the "Global Therapeutic Vaccines Market- Trends And Forecasts (2014-2019)" report to their offering. The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales. However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5 billion in 2000 to almost USD 24 billion in 2013. Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV are also projected to hit the magic milestone. Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. They have used significant revenues, global size, and deeper expertise to fund. The development of new technologies for vaccine development - an expensive and relatively time consuming process. But Despite the success of vaccines, infectious diseases are still a major cause of illnesses worldwide and at least 40 major infectious diseases are still uncontrolled by vaccination. There are currently close 120 new vaccines in the pipeline of various companies across the globe set to hit the market in the next 5 years to come. In anticipation of this and with the emergence of new target market and smaller player into the market, the Global vaccine market is set to grow by a CAGR of close to 12.4 % till the year 2020. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Global Therapeutic Proteins Market - Industry Analysis 4. Types of Vaccines 5. Vaccine market by application ( Market Size , Forecast, CAGR) 6. Regional Analysis of the Vaccine market 7. Competitive Landscape 8. Key Company Profiles - Glaxosmithkline - Merck - Novartis - Pfizer - Sanofi Avnetis - Serum Institute For more information visit http://www.researchandmarkets.com/research/t44dgp/global
Interesting November Stock Options for MRK
StockOptionsChannel.com - Mon Sep 29, 11:13AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Merck Partners with eSSENTIAL Accessibility to offer app for people with disabilities
CNW Group - Mon Sep 29, 8:00AM CDT
Global healthcare leader now offers a free app that makes it easier for people with disabilities to browse its websites
Global Hepatitis B Vaccines Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck and Sanofi Pasteur
PR Newswire - Mon Sep 29, 7:25AM CDT
Research and Markets has announced the addition of the "Global Hepatitis B Vaccines Market 2014-2018" report to their offering.
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer
PR Newswire - Mon Sep 29, 6:47AM CDT
Research and Markets has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering.
MSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in Patients with Advanced Bladder Cancer at ESMO 2014
Business Wire - Mon Sep 29, 4:00AM CDT
--Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014
Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
Business Wire - Mon Sep 29, 4:00AM CDT
--Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014
Product Innovations and Geographical Expansion Drive Sustained Merck Consumer Health Business Growth
Business Wire - Mon Sep 29, 3:00AM CDT
--Consumer Health remains the fastest growing division at Merck in Q2 2014
J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
Global Acaricides Market Outlook 2019 - Key Vendors are BASF SE, Arysta LifeScience, Bayer AG, DuPont & FMC Corporation
M2 - Tue Sep 30, 9:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mdhbk/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. The global acaricides market is estimated to be valued at $275.1 million by 2019, at a projected CAGR of 5.2% from 2014 Acaricides are chemicals that are manufactured and used for controlling the spread of arthropod pests. These pests, if allowed to spread, cause huge losses to agricultural crops and also infect various animals in the animal husbandry industry. There are numbers of acaricides available, which have different concentrations of various chemicals like chlorine, phosphorus, zinc, and tin. Acaricides have toxic effects too, due to which natural products like neem, clove, and spoiled corns, are also being used for the production of acaricides. These natural acaricides tend to be less toxic. The Asia-Pacific region is estimated to be the largest consumer of acaricides in the world, followed by Europe. China is estimated as the largest market in the Asia-Pacific, having captured around 44% of the total market in the region, in 2013. This market is growing steadily due to an increase in the usage of crop protection chemicals to control the spread of ticks and mite-borne diseases. The demand-driving factors of this market are developments in the crop protection industry and the rise in demand for meat and dairy products. The restraining factors are the regulatory restrictions in some countries and the rising cost of acaricides. Key participants in the acaricides market are BASF SE (Germany), Arysta LifeScience (Japan), Bayer AG (Germany), DuPont (U.S.), and FMC Corporation (U.S.). The acaricides market is witnessing rapid development in the areas of new product launches, with a focus on increasing the availability of various acaricides in the market and also on increasing their global market share. Scope Of The Report By type - Organochlorine - Organophosphorus - Natural - Others By application - Agriculture - Animal Husbandry - Industrial - Others By mode of application - Spray - Dipping vat - Hand dressing - Others Companies Mentioned - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/9m...des_market
Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
Glaucoma Treatment Market 2014-2019 Global Trends & Opportunities Reviewed in New Research Report
PR Newswire - Tue Sep 30, 7:30AM CDT
MarketReportsOnline.com adds Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) research report that provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Complete report is available at http://www.marketreportsonline.com/357921.html .
Inovio Pharmaceuticals Appoints Vice President of Commercial Development
PR Newswire - Tue Sep 30, 6:00AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into phase III, Ms. Laux will direct commercial development for the company's immunotherapies to treat HPV and the pre-cancers and cancers caused by this infection.
Global and Chinese Chemical Reagent Industry Report 2014-2017
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjcjmv/global_and) has announced the addition of the "Global and Chinese Chemical Reagent Industry Report, 2014-2017" report to their offering. Chemical reagent, purified from industrial chemicals, serves chiefly scientific experiment and detection analysis, and finds massive application in electronic information, medicine, food, aerospace and military industry manufacturing. In 2013, global chemical reagent market was worth about USD 13.6 billion, with market demand concentrated in United States, Europe and Japan. There are a large variety of chemical reagents, totaling above 250,000 around the world. American Sigma-Aldrich is the company that produces the most varieties of chemical reagents, up to approximate 230,000. Global chemical reagent industry characterizes a fairly high concentration, and American Sigma-Aldrich and German Merck Group, as industry leaders, took up a combined 30% or so market share globally in 2013. China chemical reagent industry has developed quickly, achieving a CAGR of 15.9% as concerns market size during 2007-2013, and making up 19.2% of global market size. Chemical reagent can be divided into general reagent and high-purity reagent, with the latter accounting for about 26% of total market size in China in 2013. High-purity chemical reagent is mainly used in semiconductor industry, and is the product that enjoys the fastest growth rate and has the highest technical content and added value. With the rapid development of China's electronic information, biotechnology, national defense, military industry and other industries, the demand for high purity reagent will keep a roughly 15% growth rate over the next couple years. In 2013, there were more than 400 chemical reagent producers with production licenses in China, most of which focused on low-end products, resulting in fierce competition in the low-end market; by contrast, the high-end market is dominated by transnational companies, such as German Merck Group and American Sigma-Aldrich, which held a combined 16.9% market share in China in 2013. In recent years, concentration of China chemical reagent industry has been improving gradually, mainly reflected by rapid development of large chemical reagent companies. Moreover, China-made chemical reagents are advancing from the low-end to the middle and high-end, with some imported products having been substituted with domestic ones. Typical domestic companies include Xilong Chemical Co., Ltd. and Sinopharm Chemical Reagent Co., Ltd., together occupying 13.2% of the Chinese market in 2013. Key Topics Covered: 1. Overview of Chemical Reagent 2. Chemical Reagent Market 3. Chinese Chemical Reagent Market 4. Foreign Companies 5. Chinese Companies 6. Summary and Forecast Companies Mentioned - Anhui Fulltime Specialized Solvent & Reagent - Danaher - Guangdong Guanghua Sci-Tech - Jianghua Microelectronics Materials - Jiangyin Chemical Reagent Factory - Johnson Matthey - Merck Group - Sigma-Aldrich - Sinopharm Group - Suzhou Crystal Clear Chemical - Suzhou JIMCEL Electronic New Material - TCI - Thermo Fisher - Wako - Xilong Chemical For more information visit http://www.researchandmarkets.com/research/sjcjmv/global_and
Hospital Infection Therapeutics (Antibacterial, Antiviral and Antifungal Drugs) Market - Global Pipeline Analysis 2014-2020
M2 - Tue Sep 30, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4q7d8p/hospital) has announced the addition of the "Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future. North America dominates the global hospital infection therapeutics market followed by the European market in 2013. Key factors contributing to the growth of the region are high prevalence of various hospital infections, rising number of multi-drug resistant microbial pathogens, increasing demand for advanced therapeutics, and high ratio of hospitals per thousand of the population. This region also comprises huge geriatric population that are more prone towards different hospital infections due to their lowered immunity levels, hence require use of various antimicrobial therapeutics, which in turn will contribute towards the growth of this market. Asia-Pacific represents the fastest growing geographic region in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. Key factor responsible for the rapid growth of this market is increasing prevalence of hospital-acquired infections in the region. Increasing healthcare awareness and infrastructure along with increasing purchasing power of the people will add to the growth of this market in the region. The global hospital infection therapeutics market is segmented as follows: Hospital Infection Therapeutics Market, by Drug Type - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs Hospital Infection Therapeutics Market, by Major Infections - Hospital-Acquired Pneumonia - Surgical Site Infections - Urinary Tract Infections - Gastrointestinal Disorders - Bloodstream Infections - Other Hospital Infections Companies Mentioned - Actavis plc - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline plc - Johnson & Johnson Services, Inc. - Merck & Co., Inc. - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/4q7d8p/hospital
Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 5:50PM CDT
A response from the FDA on Bristol-Myers' (BMY) Opdivo should be out by Mar 30.
Endocyte's TARGET Interim Data Positive for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:25PM CDT
Endocyte, Inc. (ECYT) announced an encouraging interim update on overall survival (OS) of patients in the phase IIb TARGET study on vintafolide for NSCLC.
Research and Markets: Global Therapeutic Vaccines Market Outlook 2019 Featuring GSK, Merck, Novartis, Pfizer, Sanofi Avnetis & Serum Institute
Business Wire - Mon Sep 29, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vl7kz/global) has announced the addition of the "Global Therapeutic Vaccines Market- Trends And Forecasts (2014-2019)" report to their offering.
Why Endocyte, Inc. Stock Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 29, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
Global Therapeutic Vaccines Market Outlook 2019 Featuring GSK, Merck, Novartis, Pfizer, Sanofi Avnetis & Serum Institute
M2 - Mon Sep 29, 11:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t44dgp/global) has announced the addition of the "Global Therapeutic Vaccines Market- Trends And Forecasts (2014-2019)" report to their offering. The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales. However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5 billion in 2000 to almost USD 24 billion in 2013. Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV are also projected to hit the magic milestone. Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. They have used significant revenues, global size, and deeper expertise to fund. The development of new technologies for vaccine development - an expensive and relatively time consuming process. But Despite the success of vaccines, infectious diseases are still a major cause of illnesses worldwide and at least 40 major infectious diseases are still uncontrolled by vaccination. There are currently close 120 new vaccines in the pipeline of various companies across the globe set to hit the market in the next 5 years to come. In anticipation of this and with the emergence of new target market and smaller player into the market, the Global vaccine market is set to grow by a CAGR of close to 12.4 % till the year 2020. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Global Therapeutic Proteins Market - Industry Analysis 4. Types of Vaccines 5. Vaccine market by application ( Market Size , Forecast, CAGR) 6. Regional Analysis of the Vaccine market 7. Competitive Landscape 8. Key Company Profiles - Glaxosmithkline - Merck - Novartis - Pfizer - Sanofi Avnetis - Serum Institute For more information visit http://www.researchandmarkets.com/research/t44dgp/global
Interesting November Stock Options for MRK
StockOptionsChannel.com - Mon Sep 29, 11:13AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Merck Partners with eSSENTIAL Accessibility to offer app for people with disabilities
CNW Group - Mon Sep 29, 8:00AM CDT
Global healthcare leader now offers a free app that makes it easier for people with disabilities to browse its websites
Global Hepatitis B Vaccines Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck and Sanofi Pasteur
PR Newswire - Mon Sep 29, 7:25AM CDT
Research and Markets has announced the addition of the "Global Hepatitis B Vaccines Market 2014-2018" report to their offering.
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer
PR Newswire - Mon Sep 29, 6:47AM CDT
Research and Markets has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering.
MSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in Patients with Advanced Bladder Cancer at ESMO 2014
Business Wire - Mon Sep 29, 4:00AM CDT
--Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014
Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
Business Wire - Mon Sep 29, 4:00AM CDT
--Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014
Product Innovations and Geographical Expansion Drive Sustained Merck Consumer Health Business Growth
Business Wire - Mon Sep 29, 3:00AM CDT
--Consumer Health remains the fastest growing division at Merck in Q2 2014
